Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2014; 20(46): 17345-17351
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17345
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17345
Table 2 Summary of previous reports on computed tomography perfusion and antiangiogenic therapy in colorectal cancer
| Ref. | Year | Number of patients | Time of CTP after the treatment | Parameter changes |
| Willet et al[18] | 2004 | 6 (primary) | After 12 d of administration of bevacizumab | BF, BV/decrease |
| Willet et al[32] | 2009 | 32 (primary) | After 12 d of administration of bevacizumab | BF, PS/decrease |
| Anzidei et al[33] | 2011 | 18 (liver metastases) | After 181 d of the treatment (including bevacizumab) | BF, BV/slightly decrease (not significant) |
- Citation: Hayano K, Fujishiro T, Sahani DV, Satoh A, Aoyagi T, Ohira G, Tochigi T, Matsubara H, Shuto K. Computed tomography perfusion imaging as a potential imaging biomarker of colorectal cancer. World J Gastroenterol 2014; 20(46): 17345-17351
- URL: https://www.wjgnet.com/1007-9327/full/v20/i46/17345.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i46.17345